Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
Findings highlight a potential positive benefit-risk profile of liso-cel over mosunetuzumab as a 3L+ treatment for R/R FL.
Authors
- Saurabh Dahiya (ORCID: https://orcid.org/0000-0001-8291-1796)
- Loretta J. Nastoupil (ORCID: https://orcid.org/0000-0001-6071-8610)
- Pearl Wang
- Jinender Kumar (ORCID: https://orcid.org/0000-0001-8490-6317)
- Thalia A. Farazi
- Lamees Almuallem
- Jigar Desai
- Ashley Bonner
Institutions
- University of Maryland, Baltimore (US)
- Bristol-Myers Squibb (United States) (US)
- Sisters of Mercy Health System (US)
- EVERSANA (Canada) (CA)
- U-M Rogel Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s40164-025-00610-1
- Citations
- 7
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.30